Glaucoma implant trial halted early – what we know

NCT ID NCT04770324

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a new medical device called Supraflow v1.3, which is implanted in the eye to help drain fluid and lower pressure in people with open-angle glaucoma. The trial included 22 patients whose eye pressure was not controlled with medication. However, the study was terminated early, so the full safety and effectiveness of the implant remain unclear.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Supraflow v1.3 medical device (interposition supraciliary implant)

What this could lead to

If successful, this implant could offer a new surgical option to lower eye pressure in glaucoma patients who don't respond well to eye drops.

What could go wrong

The trial was terminated early with only 22 participants, so we don't have enough data to know if it works or is safe. Surgery always carries risks like infection or inflammation.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLAUCOMA, OPEN-ANGLE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

open-angle glaucoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Malayan Center

    Yerevan, 0033, Armenia